SuperGen, Inc. had been a pharmaceutical company organized around oncology therapies for solid tumors, hematological malignancies and blood disorders - ahving three key compounds: Nipent, Orathecin and Decitabine - Nipent having been approved by the United States Food and Drug Administration (FDA) and marketed by the Company for the treatment of hairy cell leukemia. As of April 2007, Mitomycin and Paclitaxel rights of SuperGen, Inc., were acquired by Intas Pharmaceuticals Ltd. In 2011, Astex Therapeutics Limited (Astex), a privately held, UK-based biotechnology company developing targeted therapies. became a wholly owned subsidiay of SuperGen, Inc. Later that year, SuperGen changed its own Corporate Mame to Astex Pharmaceuticals, Inc., and from that point, was listed on NASDAQ under the symbol ASTX. In Fall 2013, Japanese drug and nutraceuticals firm Otsuka Pharmaceutical Co. Ltd. acquire Astex Pharmaceuticals Inc. for a reported $886mm. Shortly therafter Astex Pharmaceuticals Inc. and Genentech Inc. entered into a trial collaboration agreement to investigate the combination of Astex' guadecitabine with Genentech's atezolizumab for acute myeloid leukemia.
